1. Home
  2. PGEN vs EHAB Comparison

PGEN vs EHAB Comparison

Compare PGEN & EHAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGEN
  • EHAB
  • Stock Information
  • Founded
  • PGEN 1998
  • EHAB 2014
  • Country
  • PGEN United States
  • EHAB United States
  • Employees
  • PGEN N/A
  • EHAB N/A
  • Industry
  • PGEN Biotechnology: Pharmaceutical Preparations
  • EHAB Hospital/Nursing Management
  • Sector
  • PGEN Health Care
  • EHAB Health Care
  • Exchange
  • PGEN Nasdaq
  • EHAB Nasdaq
  • Market Cap
  • PGEN 493.0M
  • EHAB 403.5M
  • IPO Year
  • PGEN N/A
  • EHAB N/A
  • Fundamental
  • Price
  • PGEN $4.39
  • EHAB $8.53
  • Analyst Decision
  • PGEN Buy
  • EHAB Buy
  • Analyst Count
  • PGEN 5
  • EHAB 3
  • Target Price
  • PGEN $7.50
  • EHAB $8.67
  • AVG Volume (30 Days)
  • PGEN 5.2M
  • EHAB 311.8K
  • Earning Date
  • PGEN 11-13-2025
  • EHAB 11-05-2025
  • Dividend Yield
  • PGEN N/A
  • EHAB N/A
  • EPS Growth
  • PGEN N/A
  • EHAB N/A
  • EPS
  • PGEN N/A
  • EHAB N/A
  • Revenue
  • PGEN $4,340,000.00
  • EHAB $1,037,800,000.00
  • Revenue This Year
  • PGEN $249.10
  • EHAB $4.95
  • Revenue Next Year
  • PGEN $710.03
  • EHAB $4.51
  • P/E Ratio
  • PGEN N/A
  • EHAB N/A
  • Revenue Growth
  • PGEN N/A
  • EHAB N/A
  • 52 Week Low
  • PGEN $0.65
  • EHAB $6.47
  • 52 Week High
  • PGEN $5.23
  • EHAB $10.91
  • Technical
  • Relative Strength Index (RSI)
  • PGEN 67.29
  • EHAB 59.14
  • Support Level
  • PGEN $3.85
  • EHAB $7.89
  • Resistance Level
  • PGEN $4.24
  • EHAB $8.82
  • Average True Range (ATR)
  • PGEN 0.29
  • EHAB 0.31
  • MACD
  • PGEN 0.10
  • EHAB 0.04
  • Stochastic Oscillator
  • PGEN 92.79
  • EHAB 71.17

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

About EHAB Enhabit Inc.

Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.

Share on Social Networks: